Summary

Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE

Analysis

 The introduction of a new agent to cancer therapy is always interesting. It remains to be seen how the drug interacts with conventional chemotherapy. In some cases it orks and in others it doesn't and may even have disadvantages over chemotherapy without the new drug. It is difficult to predict how these things will turn out and this has been demonstrted tim and time again when one uses the basis for their project"if one drug works good, more will work better". the hedghog path is a tumor repir and growth pathway, but one can see how inhibiting this process can either be good or bad. The only outcome that will be a success is of course a significant improvemnt and with a disease like colorectal cancer PFS may not be enough , as there areso may regimens being developed to salvage patients.

Donald Fleming consults with leading institutions through GLG

Donald Fleming, Division Head of Hematology and Oncology

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.